Focused On-demand Library for Eukaryotic translation initiation factor 4E type 2

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

PARTNER
Receptor.AI
 
UPACC
O60573

UPID:
IF4E2_HUMAN

ALTERNATIVE NAMES:
Eukaryotic translation initiation factor 4E homologous protein; Eukaryotic translation initiation factor 4E-like 3; eIF4E-like protein 4E-LP; mRNA cap-binding protein 4EHP; mRNA cap-binding protein type 3

ALTERNATIVE UPACC:
O60573; B8ZZJ9; O75349

BACKGROUND:
The mRNA cap-binding protein 4EHP, also known as Eukaryotic translation initiation factor 4E type 2 (EIF4E2), plays a critical role in the early steps of translation initiation by binding the 7-methylguanosine cap of mRNA. Its function as a repressor of translation initiation, through competition with EIF4E and blocking the eIF4F complex assembly, highlights its significance in cellular protein synthesis. EIF4E2's involvement in miRNA-mediated translational repression and its role in the host's response to SARS-CoV-2 infection by controlling the translation of innate immune response genes underscore its potential impact on therapeutic interventions.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Eukaryotic translation initiation factor 4E type 2 offers a promising avenue for the development of novel therapeutic approaches, particularly in enhancing antiviral responses and modulating immune system activities.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8422 of 8789